(RNAZ) Moves Approx. 22% This Morning After New Trial Data Hits—You Watching?

*Sponsored Jeff Ackerman Shines the Spotlight on TransCode Therapeutics (Nasdaq: RNAZ) Here’s Why (RNAZ) Just Hit Our Radar This Morning—Thursday, May 1, 2025… Analyst Target From HC Wainwright Set At $10 For (RNAZ), Reported By Benzinga, Suggests Over 2,250% Upside Potential. (RNAZ) Float is Listed as Under 21M Shares—Which Could Set The Stage For Big Swing Potential If Demand Begins To Shift.  (RNAZ) Recently Moved Approximately 93% Inside Of Nine Sessions, From $0.2196 To $0.425 While Breaking Key Moving Averages. FDA Granted Orphan Designation For TTX-MC138 In Pancreatic Cancer, Underscoring Scientific And Regulatory Alignment. Preclinical Models Showed TTX-MC138 Triggered Complete Regression In Advanced Metastatic Cancer Studies. Pull Up (RNAZ) While It’s Still Early… May 1, 2025 Dear Reader, This morning’s clinical update—first reported by Benzinga—has put TransCode Therapeutics (Nasdaq: RNAZ) in the spotlight. The company has now dosed 13 patients in its Phase 1 trial of TTX-MC138, and so far, no significant safety issues have been reported. Two of those patients remain on therapy after seven full months, holding stable disease against metastatic cancer. Early human data is confirming what the science aimed for: direct engagement with miRNA-10b, a genetic driver linked to the spread of cancer.  And with the FDA already granting Orphan Designation for pancreatic cancer, this program is gaining traction fast. In the early session, (RNAZ) moved approximately 22%, reaching $0.497 from yesterday’s close of $0.4066. With strong preclinical alignment, zero dose-limiting toxicities so far, and real human data now stacking up, (RNAZ) has our full attention today.  If you missed my earlier coverage, keep reading to get up to speed on (RNAZ). Every once in a while, a company that’s been quietly grinding in the background starts to break through the noise. Not with hype. But with hard data. TransCode Therapeutics (Nasdaq: RNAZ) is one of those companies... And now, more than just early clinical progress is drawing attention. Benzinga reports that just a few weeks ago, HC Wainwright & Co.—one of the oldest firms in the country—set their target on RNAZ at $10.  That suggests an upside potential of more than 2,250% from yesterday’s open of $0.425. That $10 target didn’t come out of nowhere. Over the past 9 sessions alone, (RNAZ) has quietly moved approximately 93%, from $0.2196 on April 17 to $0.425 yesterday (April 30, 2025)—pushing above its 5- and 20-day moving averages. With its 50-day moving average still way up at $1.5253, we have all eyes on (RNAZ) right now. But keep in mind, (RNAZ) has less than 21M shares in its float—which could set the stage for potential swings if demand begins to shift. Keep reading to see why (RNAZ) is topping our watchlist this morning… Real Human Data—and It’s Delivering Signals… One of the most compelling reasons (RNAZ) is on watch right now is that their science is already in humans—and showing activity.  Their lead therapeutic, TTX-MC138, is currently in a Phase 1a trial, but what truly sets this program apart is what’s already been observed in a prior Phase 0 microdose study.  The compound didn’t just circulate—it reached metastatic lesions in the liver, lungs, and bones of a real human patient.  Even at subtherapeutic doses, it triggered measurable pharmacodynamic activity in blood samples, offering early validation that the therapy is targeting cancer-driving microRNA inside the body. FDA Signals Green Light on a Tough-to-Treat Killer… Adding to the momentum, the FDA has granted Orphan Designation for pancreatic cancer, one of the deadliest and most challenging types to treat.  This signals a strong degree of regulatory alignment and highlights the clinical significance of their target, miRNA-10b, which has been closely linked to the spread and progression of multiple aggressive cancers. More Than a Molecule—It’s a Platform… But this isn’t a single-shot pipeline.  TransCode Therapeutics (Nasdaq: RNAZ)’s delivery system has broad potential across multiple RNA modalities, capable of transporting siRNA, antisense oligos, and immunostimulatory payloads with high precision.  The company is already expanding the platform with new candidates—TTX-siPDL1, a checkpoint inhibitor designed to improve immune engagement, and TTX-RIGA, which aims to activate the body’s innate immune response to help eliminate tumors from within. In Preclinical Models—Complete Regressions… Backing this clinical ambition is animal data that’s hard to overlook. In both murine models and spontaneous feline cancers, TTX-MC138 has delivered complete regressions of metastatic disease and extended survival significantly—even in late-stage cases.  These results speak to the potential power of the platform when it translates from lab to clinic. Recent Clinical Activity Confirmed… On March 27, 2025, TransCode announced that it had initiated dosing in its fourth cohort of the ongoing Phase 1 trial for TTX-MC138. This marks a key step forward in the program, with ten patients now treated at escalating dose levels.  The company’s ability to progress this trial without interruption adds meaningful weight to its early-stage development and reinforces that momentum is not just theoretical—it’s being measured one patient at a time. Now that they’ve proven the delivery system can reach the hardest-to-hit areas—metastatic sites—the company is rolling out new candidates using the same backbone. Their siRNA-based checkpoint inhibitor (TTX-siPDL1) has already shown potential to regress pancreatic tumors by ~90% in animal models when combined with chemo. Another, TTX-RIGA, is being positioned as an immune trigger with possible impact across recurrent or deep-tissue tumors. The pipeline is no longer just one bullet.  It’s a modular platform—one with the potential to address multiple angles of cancer treatment using custom-built RNA tools. And right now, that platform is finally stepping out of the shadows and into the spotlight. With key milestones stacking up—and the clinical picture coming into sharper focus—there’s real reason to be paying attention. 7 Reasons Why TransCode Therapeutics (Nasdaq: RNAZ) is Topping Our Watchlist This Morning… 1. Analyst Coverage: HC Wainwright & Co., one of the longest-standing names on the street, recently set their target on (RNAZ) at $10, as reported by Benzinga. That figure suggests over 2,250% upside potential. 2. Low Float: With a float reportedly under 21M shares and over $62M raised without excessive dilution, (RNAZ) stands out structurally. That combination—fiscal runway with a tight share count—can often be a potential catalyst if demand begins to shift. 3. Recent Market Recognition: In just the last 9 sessions, (RNAZ) moved approximately 93%, from $0.2196 on April 17 to $0.425 by April 30, 2025. That kind of move—especially while surpassing its 5 and 20-day moving averages—can signal growing interest and the potential for continued momentum. 4. Real Human Data in the Clinic—And It’s Delivering: Their lead RNA-based therapeutic, TTX-MC138, has already been evaluated in a human Phase 0 study. Imaging showed the compound reached metastatic lesions in the liver, lung, and bone, and lab results showed significant target activity—demonstrated even at low doses. 5. Recognized by the FDA with Orphan Designation: The FDA granted Orphan Designation for TTX-MC138 in pancreatic cancer—a notoriously difficult disease. This designation supports the seriousness of the science and indicates alignment with regulators focused on unmet needs. 6. More Than a One-Off—This Is a True RNA Platform: (RNAZ) isn’t limited to one candidate. Their delivery platform supports a variety of payloads including siRNA, antisense, and immune activators. Two new candidates—TTX-siPDL1 and TTX-RIGA—are already in development, extending the reach of the platform across multiple targets and tumor types. 7. From Terminal to Tumor-Free—What the Models Revealed: In preclinical studies, TTX-MC138 delivered more than just a slowdown—it triggered complete regressions in advanced metastatic cancer models.  See Why (RNAZ) Is Front and Center On This Morning’s Radar… As the curtain lifts on RNA-based platforms built for precision, few names are drawing attention like TransCode Therapeutics, Inc. (Nasdaq: RNAZ). With one of the street’s oldest firms—HC Wainwright & Co.—recently assigning a $10 target, and (RNAZ) moving approximately 93% over the past nine sessions, momentum is being matched by hard fundamentals.  A small float under 21M shares, over $62M raised, and real human data confirming tumor targeting puts (RNAZ) in a rare category. Add in FDA Orphan Designation, a modular RNA platform with multiple programs in development, and full tumor regressions in preclinical models—and you begin to understand why this name is finally starting to show up on more screens. We have all eyes on (RNAZ) this morning.  Consider taking a look at (RNAZ) while it’s still early. In the early session, (RNAZ) moved approximately 22%, reaching $0.497 from yesterday’s close of $0.4066. Are you watching this yet?  My next update could be out at any moment—keep an eye out for it. Sincerely, Jeff Ackerman Managing Editor Stock News Trends StockNewsTrends.com (“StockNewsTrends” or “SNT” ) is owned by TD Media LLC, a single member limited liability company. Data is provided from third-party sources and StockNewsTrends is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SNT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owner of TD Media LLC owns and operates stocknewstrends . com (“SNT”). From time to time, SNT will publicly disseminate information about a company via website, email, SMS and other points of media. *Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 04/30/2025 and ending on 05/01/2025 to publicly disseminate information about (RNAZ:US) via digital communications. Under this agreement, TD Media LLC has been paid fifty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither TD Media LLC and their member own shares of (RNAZ:US). Please see important disclosure information here: https://lifewatermedia.com/disclosure/rnaz-8m3bh/#details

TD Media LLC | 5826 New Territory Blvd. Unit #2144 | Sugar Land, TX 77479 US Unsubscribe | Update Profile | Constant Contact Data Notice